Clinical Observation of Anshen Buxin Cream in Treating Coronary Heart Disease with Somatization Disorder After PCI

INTERVENTION: Experimental group:Oral Anshen Buxin Paste;Control group:Anshen Buxin Paste Placebo Oral; CONDITION: Coronary heart disease post‐PCI with comorbid somatization disorder PRIMARY OUTCOME: Severity of somatization disorder; SECONDARY OUTCOME: Level of anxiety;Severity of depression;Sleep condition;Traditional Chinese Medicine Syndrome Scoring;Heart rate variability measurement; INCLUSION CRITERIA: 1) Meets the above diagnostic criteria of Western medicine and Traditional Chinese Medicine, aged over 18 years and under 85 years; 2) The patient is conscious and able to answer questions independently and clearly; 3) Signed the informed consent form and agreed to participate in this follow‐up treatment observation.